Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer

JAMA Internal Medicine

Volumn 174, Issue 9, 2014, Pages 1460-1467

  Lu Yao, Grace L ^a,b,d   Albertsen, Peter C ^c   Moore, Dirk F ^a,b   Shih, Weichung ^a,b   Lin, Yong ^a,b   DiPaola, Robert S ^a,d   Yao, Siu Long ^a,e  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d Dean and Betty Gallo Prostate Cancer Center   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; GONADORELIN ANTAGONIST; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BILATERAL ORCHIECTOMY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; LOCALIZED PROSTATE CANCER; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OVERALL SURVIVAL; POPULATION RESEARCH; PROSTATE CANCER; SURVIVAL RATE; TREATMENT OUTCOME; CANCER GRADING; CANCER STAGING; MEDICARE; MORTALITY; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; MEDICARE; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; SEER PROGRAM; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84907015061     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3028     Document Type: Article

References (30)

1. CooperbergMR, Broering JM, Litwin MS, et al; CaPSURE Investigators. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol. 2004;171(4): 1393-1401.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#prostate. Accessed January 30, 2013.
3. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropinreleasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8): 1615-1624.
4. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-181.
5. Studer UE, Collette L, Whelan P, et al; EORTC Genitourinary Group. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol. 2008;53(5): 941-949.
6. Shao YH, Moore DF, ShihW, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013;111(5):745-752.
7. Lu-Yao GL, Albertsen PC, Li H, et al. Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol. 2012;62(6):966-972.
8. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
9. Medicare and Medicaid Statistical Supplement, 2013. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/2013.html. Accessed December 10, 2013.
10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164.
11. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132(7):566-577.
12. Dolan M, Kim S, Shao YH, Lu-Yao G. Authentication of algorithm to detectmetastases in men with prostate cancer using ICD-9 codes. Epidemiol Res Int. 2012. doi:10.1155/2012/970406.
13. Albertsen PC,Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol. 2000;163(2): 519-523.
14. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93(23):1822-1823.
15. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274(8):626-631.
16. Fowler JE Jr, Terrell FL, Renfroe DL. Comorbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol. 1996;156(5):1714-1718.
17. D'HooreW, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med. 1993;32(5):382-387.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45 (6):613-619.
19. Klabunde CN, Potosky AL, Legler JM,Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53 (12):1258-1267.
20. Makuc D, Haglund B, Ingram D, Kleinman J, Feldman J. Vital and Health Statistics: Health Service Areas for the United States. Hyattsville, MD: National Center for Health Statistics; 1991.
21. Angrist J, Imbens G, Rubin D. Identification of causal effects using instrumental variables. J Am Stat Assn. 1996;91(434):444-455.
22. Therneau T. coxme: mixed effects Cox models. R package, version 2.2.3. http://cran.r-project.org/web/packages/coxme. Accessed December 10, 2013.
23. Therneau TM, Grambach PM, Pankratz VS. Penalized survival models and frailty. J Comput Graphical Statistics. 2003;12(1):156-175.
24. R Core Team R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. http://www.r-project.org. Accessed June 5, 2014.
25. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
26. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
27. Studer UE, Whelan P, Wimpissinger F, et al; EORTC Genitourinary Cancer Group. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC Randomized Trial 30891 with 12 years of follow-up [published online July 24, 2013]. Eur Urol. doi:10 .1016/j.eururo.2013.07.024.
28. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997;79(2):235-246.
29. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106(8): 1708-1714.
30. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst. 2006;98(12):839-845.